Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
May 13, 2024 08:00 ET
|
Merus N.V.
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage...
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 08, 2024 16:15 ET
|
Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by...
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
May 06, 2024 16:05 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
April 08, 2024 12:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
March 05, 2024 16:30 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
March 04, 2024 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
February 28, 2024 16:15 ET
|
Merus N.V.
- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial...
Merus nimmt an bevorstehenden Investorenkonferenzen teil
January 31, 2024 14:06 ET
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., USA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen im Bereich der klinischen Onkologie, das innovative multispezifische...
Merus annonce la tenue d’une série de conférences auprès des investisseurs
January 31, 2024 14:06 ET
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 31 janv. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de...
Merus to Participate in Upcoming Investor Conferences
January 31, 2024 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...